We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Neogen (NEOG) Up 3.6% Since Last Earnings Report: Can It Continue?
Read MoreHide Full Article
It has been about a month since the last earnings report for Neogen (NEOG - Free Report) . Shares have added about 3.6% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Neogen due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Neogen's Q1 Earnings Lag Estimates, Margins Rise
Neogen reported first-quarter fiscal 2024 earnings per share of 11 cents, down 31.3% year over year. The reported figure missed the Zacks Consensus Estimate by 21.4%.
Revenues for the fiscal first quarter increased 73% on a year-over-year basis to $228.9 million. Core revenues declined 1.3%. Acquisitions and discontinued product lines contributed 73.5%. The metric missed the Zacks Consensus Estimate by 1.2%. Per management, the Animal Safety business experienced continued destocking as anticipated, with channel inventory levels reaching multi-year lows.
Segments in Detail
Within segments, Neogen registered Food Safety revenues of $166.3 million in the fiscal first quarter, marking a stupendous 157.2% improvement from $64.6 million in the prior-year period, led by 4.5% core growth and 150.7% growth from acquisitions. The reported figure also exceeded our model’s segmental projection of $150.1 million for the first quarter.
Core growth within this segment was led by the Bacterial & General Sanitation product category, which benefited from new microbiological testing business in the United States and the United Kingdom and solid growth in the Natural Toxins and Allergens product category.
Revenues from Animal Safety were $62.7 million, down 7.4% year over year. Within the segment, the core revenue decline of 6.7% was due to the Veterinary Instruments and Disposables product category, which experienced continued destocking by large veterinary distributors, and the Animal Care and Other product category, which had lower sales of small-animal supplements and vitamin injectables, due in part to supply constraints. These decreases were partially offset by growth in the Rodent Control, Insect Control and Cleaners and Disinfectants product categories. The reported figure missed our model’s segmental projection of $82 million for the first quarter.
The company's worldwide genomics business declined modestly in the quarter as strength in sheep and beef testing in Australia and new business in beef markets in the United Kingdom and Brazil were offset by decreases in porcine and poultry testing due to two large domestic customer losses.
Margin Details
Neogen’s fiscal first-quarter gross profit increased 87.5% year over year to $116.8 million. The gross margin expanded 394 basis points (bps) to 50.9%. The increase was led by higher gross margins generated by incremental revenues from the former 3M Food Safety Division.
Sales and marketing expenses rose 95.7% to $45.8 million, whereas administrative expenses rose 61.5% from the prior-year quarter to $45.1 million. R&D expenses were $6.7 million, up 37.7% year over year. Operating costs totaled $97.6 million, up 73.7% from the last year’s quarter.
The company reported an operating profit of $19.1 million for the quarter under review. The adjusted operating margin expanded 378 bps to 8.4%.
Cash Position
Neogen exited the first quarter of fiscal 2024 with cash and investments of $178.8 million, compared with $163.2 million at the end of the fiscal fourth quarter of 2023. At fiscal first-quarter end, the company’s non-current liabilities included a total outstanding debt of $900 million as well as committed borrowing headroom of $150 million.
Full-Year Guidance
Neogen updated its outlook for fiscal 2024.
The company continues to anticipate full-year revenues in the band of $955 million-$985 million. The Zacks Consensus Estimate for the same is currently pegged at $966.2 million.
NEOG expects capital expenditures to be approximately $130 million, which includes approximately $100 million related specifically to the integration of the former 3M Food Safety Division (unchanged).
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates.
The consensus estimate has shifted -6.45% due to these changes.
VGM Scores
At this time, Neogen has an average Growth Score of C, though it is lagging a bit on the Momentum Score front with a D. Charting a somewhat similar path, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of this revision indicates a downward shift. Notably, Neogen has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Neogen (NEOG) Up 3.6% Since Last Earnings Report: Can It Continue?
It has been about a month since the last earnings report for Neogen (NEOG - Free Report) . Shares have added about 3.6% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Neogen due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Neogen's Q1 Earnings Lag Estimates, Margins Rise
Neogen reported first-quarter fiscal 2024 earnings per share of 11 cents, down 31.3% year over year. The reported figure missed the Zacks Consensus Estimate by 21.4%.
Revenues for the fiscal first quarter increased 73% on a year-over-year basis to $228.9 million. Core revenues declined 1.3%. Acquisitions and discontinued product lines contributed 73.5%. The metric missed the Zacks Consensus Estimate by 1.2%. Per management, the Animal Safety business experienced continued destocking as anticipated, with channel inventory levels reaching multi-year lows.
Segments in Detail
Within segments, Neogen registered Food Safety revenues of $166.3 million in the fiscal first quarter, marking a stupendous 157.2% improvement from $64.6 million in the prior-year period, led by 4.5% core growth and 150.7% growth from acquisitions. The reported figure also exceeded our model’s segmental projection of $150.1 million for the first quarter.
Core growth within this segment was led by the Bacterial & General Sanitation product category, which benefited from new microbiological testing business in the United States and the United Kingdom and solid growth in the Natural Toxins and Allergens product category.
Revenues from Animal Safety were $62.7 million, down 7.4% year over year. Within the segment, the core revenue decline of 6.7% was due to the Veterinary Instruments and Disposables product category, which experienced continued destocking by large veterinary distributors, and the Animal Care and Other product category, which had lower sales of small-animal supplements and vitamin injectables, due in part to supply constraints. These decreases were partially offset by growth in the Rodent Control, Insect Control and Cleaners and Disinfectants product categories. The reported figure missed our model’s segmental projection of $82 million for the first quarter.
The company's worldwide genomics business declined modestly in the quarter as strength in sheep and beef testing in Australia and new business in beef markets in the United Kingdom and Brazil were offset by decreases in porcine and poultry testing due to two large domestic customer losses.
Margin Details
Neogen’s fiscal first-quarter gross profit increased 87.5% year over year to $116.8 million. The gross margin expanded 394 basis points (bps) to 50.9%. The increase was led by higher gross margins generated by incremental revenues from the former 3M Food Safety Division.
Sales and marketing expenses rose 95.7% to $45.8 million, whereas administrative expenses rose 61.5% from the prior-year quarter to $45.1 million. R&D expenses were $6.7 million, up 37.7% year over year. Operating costs totaled $97.6 million, up 73.7% from the last year’s quarter.
The company reported an operating profit of $19.1 million for the quarter under review. The adjusted operating margin expanded 378 bps to 8.4%.
Cash Position
Neogen exited the first quarter of fiscal 2024 with cash and investments of $178.8 million, compared with $163.2 million at the end of the fiscal fourth quarter of 2023. At fiscal first-quarter end, the company’s non-current liabilities included a total outstanding debt of $900 million as well as committed borrowing headroom of $150 million.
Full-Year Guidance
Neogen updated its outlook for fiscal 2024.
The company continues to anticipate full-year revenues in the band of $955 million-$985 million. The Zacks Consensus Estimate for the same is currently pegged at $966.2 million.
NEOG expects capital expenditures to be approximately $130 million, which includes approximately $100 million related specifically to the integration of the former 3M Food Safety Division (unchanged).
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates.
The consensus estimate has shifted -6.45% due to these changes.
VGM Scores
At this time, Neogen has an average Growth Score of C, though it is lagging a bit on the Momentum Score front with a D. Charting a somewhat similar path, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of this revision indicates a downward shift. Notably, Neogen has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.